Skip to main content

Table 3 Endoscopic finding of the two studied groups

From: Survival benefits of adding simvastatin to standard therapy for secondary prevention of bleeding esophageal varices in patients with hepatitis C-related liver cirrhosis

Endoscope Group I Group II X2 p-value
15 days Grade 2 N 21 24 2.237 0.327
% 52.5% 60.0%
Grade 3 N 13 14
% 32.5% 35.0%
Grade 4 N 6 2
% 15.0% 5.0%
3 months Grade 2 N 22 31 5.901 0.052
% 55.0% 77.5%
Grade 3 N 12 8
% 30.0% 20.0%
Grade 4 N 6 1
% 15.0% 2.5%
6 months Grade 2 N 27 33 5.667 0.059
% 67.5% 82.5%
Grade 3 N 8 7
% 20.0% 17.5%
Grade 4 N 5 0
% 12.5% .0%
9 months Grade 2 N 32 35 3.134 0.209
% 80.0% 87.5%
Grade 3 N 5 5
% 12.5% 12.5%
Grade 4 N 3 0
% 7.5% .0%
12 months Grade 2 N 32 35 3.134 0.209
% 80.0% 87.5%
Grade 3 N 5 5
% 12.5% 12.5%
Grade 4 N 3 0
% 7.5% 0%